ReviewMolecular biology reports2026
The underexplored role of neuropilins in chronic pain pathophysiology: a review.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Chronic pain is a pervasive condition affecting over 1.5 billion people globally; and imposes a significant financial and emotional strain on individuals and society. Despite advancements in treatment, current therapies often yield incomplete relief and may pose adverse effects, underscoring the need for novel approaches. Neuropilins (NRPs) transmembrane glycoprotein functioning as co-receptors for class 3 semaphorins and vascular endothelial growth factor (VEGF) family members have emerged as promising therapeutic targets. Neuropilin-1 (Nrp-1) is implicated in chronic pain via interactions with VEGF and transforming growth factor-beta (TGF-β), promoting macrophage migration and microglial reactivity. These interactions lead to the release of pro-inflammatory cytokines and contribute to astrogliosis and glial scar formation, which disrupt neuronal signaling and exacerbate chronic pain. Conversely, Nrp-1 alleviates pain through Sema3A binding, influencing neuronal plasticity and inhibiting pain pathways. This review underscores the multifaceted role of NRPs complex pathophysiology of chronic NRPs’ pain. NRPs emerge as critical players, influencing both inflammatory processes and neuronal modulation. Nanotechnology-based drug delivery systems show promise in targeting NRP receptors specifically, enhancing therapeutic efficacy and minimizing side effects. These systems utilize various carriers like liposomes, nanoparticles, and exosomes to deliver drugs directly to NRP-expressing cells. By strategically modulating NRP interactions and signaling pathways, it may be feasible to concurrently address both the inflammatory and neuronal components of chronic pain, potentially offering novel therapeutic avenues for the patients.
Indexed as
Identifiers
41483260What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.